Evercore ISI Group Maintains Outperform on ProQR Therapeutics, Raises Price Target to $6
Benzinga Newsdesk 4 months ago
Analyst RatingsNewsPrice Target
Evercore ISI Group analyst Gavin Clark-Gartner maintains ProQR Therapeutics (NASDAQ:PRQR) with a Outperform and raises the price target from $5 to $6.
Evercore ISI Group analyst Gavin Clark-Gartner maintains ProQR Therapeutics (NASDAQ:PRQR) with a Outperform and raises the price target from $5 to $6.